文献速递前列腺癌

基于数字病理的人工智能生物标志物在转移性前列腺癌中的验证

Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2024-12-10

本研究利用3期CHAARTED试验数据,对456例转移性激素敏感性前列腺癌(mHSPC)患者评估多模态人工智能(MMAI)生物标志物的预后能力。MMAI评分与总生存(OS)、临床进展(CP)和去势抵抗性前列腺癌(CRPC)均相关,且经治疗、肿瘤负荷和诊断分期调整后仍具预后价值。

要点

  • MMAI评分高组5年OS为39%,中组58%,低组83%(log-rank p < 0.001)。
  • MMAI评分与OS(HR 1.51,95%CI 1.33-1.73;p < 0.001)、CP(subdistribution HR 1.54,95%CI 1.36-1.74;p < 0.001)和CRPC(subdistribution HR 1.63,95%CI 1.45-1.83;p < 0.001)相关。
  • MMAI生物标志物在调整治疗、肿瘤负荷状态和诊断分期后仍具预后价值。

核心结论

  • MMAI生物标志物在mHSPC患者中对OS、CP和CRPC具有预后价值,且与临床亚组或所接受治疗无关。
  • 作者认为有必要在晚期前列腺癌中进一步研究MMAI生物标志物。

研究设计与样本

  • 研究使用3期CHAARTED试验数据,790例mHSPC患者中456例有可评估的数字组织病理图像和必要临床变量以生成MMAI评分并纳入分析。
  • 通过单变量Cox比例风险模型和Fine-Gray模型评估MMAI评分与OS、CP和CRPC的关联。

主要发现

  • 分析队列中370例(81.1%)为MMAI高风险,86例(18.9%)为MMAI中/低风险。
  • 估计5年OS在MMAI高风险组为39%,MMAI中风险组为58%,MMAI低风险组为83%(log-rank p < 0.001)。
  • MMAI评分与OS相关(HR 1.51,95%CI 1.33-1.73;p < 0.001),与CP相关(subdistribution HR 1.54,95%CI 1.36-1.74;p < 0.001),与CRPC相关(subdistribution HR 1.63,95%CI 1.45-1.83;p < 0.001)。
  • MMAI高风险病例比例在低体积异时性(n = 74)亚组为50.0%,低体积同时性(n = 80)亚组为83.7%,高体积异时性(n = 48)亚组为66.7%,高体积同时性(n = 254)亚组为92.1%。
  • MMAI生物标志物在调整治疗、肿瘤负荷状态和诊断分期后仍具预后价值。

临床怎么用

  • 作者认为这些结果显示了AI工具在帮助患者及其医疗团队制定治疗决策方面的潜在获益。

局限性

  • 作者认为有必要在晚期前列腺癌中进一步研究MMAI生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Owing to the expansion of treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) and an appreciation of clinical subgroups with differential prognosis and treatment responses, prognostic and predictive biomarkers are needed to personalize care in this setting. Our aim was to evaluate a multimodal artificial intelligence (MMAI) biomarker for prognostic ability in mHSPC. METHODS: We used data from the phase 3 CHAARTED trial; 456/790 patients with mHSPC had evaluable digital histopathology images and requisite clinical variables to generate MMAI scores for inclusion in our analysis. We assessed the association of MMAI score with overall survival (OS), clinical progression (CP), and castration-resistant PC (CRPC) via univariable Cox proportional-hazards and Fine-Gray models. KEY FINDINGS AND LIMITATIONS: In the analysis cohort, 370 patients (81.1%) were classified as MMAI-high and 86 (18.9%) as MMAI-intermediate/low risk. Estimated 5-yr OS was 39% for the MMAI-high, 58% for the MMAI-intermediate, and 83% for the MMAI-low groups (log-rank p < 0.001). The MMAI score was associated with OS (hazard ratio [HR] 1.51, 95% confidence interval [CI] 1.33-1.73; p < 0.001), CP (subdistribution HR 1.54, 95% CI 1.36-1.74; p < 0.001), and CRPC (subdistribution HR 1.63, 95% CI 1.45-1.83; p < 0.001). The proportion of MMAI-high cases was 50.0%, 83.7%, 66.7%, and 92.1% in the subgroups with low-volume metachronous (n = 74), low-volume synchronous (n = 80), high-volume metachronous (n = 48), and high-volume synchronous (n = 254) mHSPC, respectively. The MMAI biomarker remained prognostic after adjustment for treatment, volume status, and diagnosis stage. CONCLUSIONS AND CLINICAL IMPLICATIONS: Our findings show that the MMAI biomarker is prognostic for OS, CP, and CRPC among patients with mHSPC, regardless of clinical subgroup or treatment received. Further investigations of MMAI biomarkers in advanced PC are warranted. PATIENT SUMMARY: We looked at the performance of an artificial intelligence (AI) tool that interprets images of samples of prostate cancer tissue in a group of men whose cancer had spread beyond the prostate. The AI tool was able to identify patients at higher risk of worse outcomes. These results show the potential benefit of AI tools in helping patients and their health care team in making treatment decisions.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Markowski MC, Ren Y, Tierney M, et al. Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer. Eur Urol Oncol. 2024. PMID: 39665917. doi:10.1016/j.euo.2024.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。